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httpEarly report from an investigator-initiated
investigational device exemption clinical trial
on physician-modiﬁed endovascular grafts
Benjamin Ware Starnes, MD, and Billi Tatum, RN, CRCC, Seattle, Wash
Objective: To determine whether a physician-modiﬁed endovascular graft (PMEG) is a safe and effective method for
treating patients with juxtarenal aortic aneurysms who are deemed unsuitable for open repair.
Methods: A nonrandomized, prospective, consecutively enrolling investigational device exemption clinical trial was used.
Data collected on patients treated with PMEG between April 2011 and August 2012 were analyzed. Subjects were
followed with computed tomography, visceral duplex, and four-view X-ray at 30 days, 6 months, and 1 year. The protocol
was designed to include follow-up to 5 years. The primary safety end point was the proportion of subjects who experi-
enced a major adverse event (MAE) within 30 days of the procedure. The primary efﬁcacy end point was the proportion of
subjects experiencing treatment success.
Results: During the 16-month study period, 28 patients were consented and 26 underwent endovascular repair using
PMEGs. Anatomic, operative details, and length of stay were recorded and included aneurysm diameter (mean, 62.5 mm),
proximal neck length (mean, 4.4mm), graft manufacture time (mean, 59.7minutes), procedure time (mean, 169minutes),
ﬂuoroscopy time (mean, 42.8 minutes), total contrast usage (mean, 63 mL), estimated blood loss (mean, 221 mL), and
length of hospital stay (mean, 4.9 days). There were 63 fenestrations created for 48 renal arteries and 15 superior
mesenteric arteries. Renal artery fenestrations were stented whenever possible (96%) and superior mesenteric artery
fenestrations were all left unstented. There were no unanticipated adverse device events, no MAEs, and only a single
minor adverse device event treated with a successful reintervention. At 30 days, there were no type I or III endoleaks
and only four type II endoleaks (15.4%). Two patients died during the study period, one at day 23 from respiratory failure
(in-hospital and 30-day mortality [ 3.8%) and one at day 210 from urosepsis and congestive heart failure. MAEs
occurred in 11.5% of patients at 30 days. The primary efﬁcacy end point was achieved in 87.5% of patients (technical success
100%, freedom from migration, rupture or conversion, type I or III endoleaks, or sac enlargement[ 100%, 100%, 87.5%,
and 87.5%, respectively).
Conclusions: These preliminary data suggest that endovascular repair with PMEG is safe and effective for managing
patients with juxtarenal aortic aneurysms. Endovascular repair with PMEG has acceptable early rates of morbidity,
mortality, and endoleak. This endovascular aortic strategy is particularly appealing for those patients presenting with
symptomatic or ruptured aortic aneurysms until reliable off-the-shelf solutions become widely available. (J Vasc Surg
2013;58:311-7.)The management of patients presenting with juxtarenal manufacture and deliver for each patient. Unfortunately,
abdominal aortic aneurysms continues to evolve. Pure
endovascular strategies exist to manage these patients, but
currently, no “off-the-shelf” solution is available outside
of a clinical trial. On April 4, 2012, the U.S. Food and
Drug Administration (FDA) Center for Devices and Radio-
logical Health approved a customized fenestrated device
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lar graft with the adjunctive Zenith alignment stent; Cook,
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Our group recently reported our experience in
managing 47 patients over a 3-year period with immediate
physician-modiﬁed endovascular grafts (PMEGs) for the
management of patients presenting with asymptomatic,
symptomatic, or ruptured juxtarenal abdominal aortic
aneurysms with limited options for repair.1 Encouraged
by our initial results, we sought an investigator-sponsored
investigational device exemption (IDE) with the FDA to
prospectively study this mode of therapy. Presented herein
are early results of this IDE clinical trial.
METHODS
This clinical trial is in compliance with all FDA regula-
tions, policies, and procedures governing IDEs and is regis-
tered with www.clinicaltrials.gov (Identiﬁer # NCT015380
56). The FDA granted approval to commence this trial on
January 26, 2011 with up to 150 subjects to enroll. This
study is also approved by the Human Subjects Division at
the University of Washington in Seattle. All patients under-
went informed consent and agreed to participate in the311
Table I. Anatomic inclusion criteria
Anatomic criterion Parameter
Proximal neck diameter, mm 20-32 (OD)
Proximal neck length, mm $2
Juxtarenal aortic angle,  <60
Iliac diameter, mm 8-20 (OD)
Iliac length (distal seal zone), mm $15
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a juxtarenal abdominal aortic aneurysm greater than 5.5
cm or with recent evidence of rapid growth are listed in
Table I.
Study description and objectives. This is a prospec-
tive, consecutively enrolling, nonrandomized single-institu-
tion clinical evaluation of the safety and efﬁcacy of physician
modiﬁcation of a currently FDA-approved off-the-shelf
aortic stent graft (Cook Zenith Flex-TFFB) to preserve
branch vessels when used in the treatment of patients with
asymptomatic, symptomatic, or ruptured juxtarenal aortic
aneurysms with no other options for repair.
The safety of PMEGs will be determined by evaluating
the proportion of patients that experience a rate of major
adverse events (MAEs). The MAE rate was compared
with a performance goal.
The efﬁcacy of PMEGs will be determined by evalu-
ating the proportion of patients that achieve treatment
success at 12 months postprocedure. The treatment success
rate was compared with a performance goal.
Study primary end points. The primary safety end
point is deﬁned as the proportion of subjects who experi-
ence an MAE within 30 days of the initial procedure.
The primary efﬁcacy end point is the proportion of subjects
that achieve treatment success. Treatment success is
a composite end point assessed at 12 months that requires
the following criteria to be met: technical success, deﬁned
as successful delivery and deployment of the PMEG with
preservation of those branch vessels intended to be
preserved, freedom from type I and III endoleaks at 12
months, freedom from stent graft migration >10 mm at
12 months, freedom from aortic aneurysm sac enlargement
>5 mm at 12 months, and freedom from aortic aneurysm
rupture and conversion to open repair through 12 months.
Study secondary end points. The following second-
ary safety end points were evaluated through 12 months:
mortality rates at 30 days and 12 months, aneurysm-related
mortality at 30 days and 12 months, MAE through 12
months, conversion to open repair and aneurysm rupture.
The secondary clinical utility end points evaluated were
procedural blood loss, duration of procedure, intensive
care unit stay, and length of hospital stay.
Follow-up intervals and events. Follow-up intervals
were 1, 6, and 12 months following the initial implant proce-
dure, then planned annually through 5 years. The follow-up
events are as follows: physical examination, ankle brachial
index at hospital discharge if history of peripheral artery
disease, contrast-enhanced spiral abdominal/pelvic computed
tomography, abdominal X-ray (KUB), including anterior-
posterior, lateral, left oblique, and right oblique projections,
device/aneurysm assessment based on imaging analysis,
laboratory assessment, and assessment of adverse events.
MAEs. MAEs included death, myocardial infarction,
stroke, renal failure, respiratory failure, paralysis, bowel
ischemia, and procedural blood loss of greater than 1 liter.
All MAEs were adjudicated by a clinical events committee
composed of three academic faculties from various medical
and surgical specialties at the University of Washington.Procedural details. Procedural details have been
previously reported.1 Three-dimensional reconstruction
imaging software (Aquarius; Tera-Recon, Foster City,
Calif) was used routinely for preoperative planning to
ensure precise placement of aortic fenestrations in “clock-
face” positions for branch vessel preservation. As the study
evolved, planning modiﬁcations were made to include arc
length measurements (Fig 1) and centerline correction for
angulated aortic anatomy (Fig 2).
Statistical analysis. This study is designed to estimate
the rate of MAEs following juxtarenal abdominal aortic
aneurysm repair with PMEG. The proportion of patients
receiving PMEG who experience one or more MAEs
within 30 days of the procedure is the rate of interest. A
target performance goal of 56% is based on the rate of
MAEs at 30 days reported for open surgical control patients
from the Society for Vascular Surgery Lifeline Registry of
Endovascular Repair.2
Treatment success is the primary efﬁcacy end point for
the study. The proportion of patients who are a treatment
success at 12 months is the rate of interest. PMEG is
considered to be effective if this study’s result veriﬁes that
the lower limit of the one-sided 95% conﬁdence interval
is above 80%. All data are presented as percentages,
means 6 standard deviation and range.
RESULTS
The ﬁrst patient (subject 001) was enrolled on March
11, 2011 and underwent successful PMEG on April 12,
2011. Data lock for this report occurred on September 1,
2012. The time from presentation to treatment averaged
19 days and ranged from 0 days (rupture) to 32 days.
During the 16-month study period, the author performed
92 subdiaphragmatic aortic aneurysm repairs; 62 (67%)
were performed using endovascular methods, 26 (28%)
were performed using traditional open surgery, and four
(4%) were hybrid procedures. Endovascular procedures
comprised 24 standard endovascular aneurysm repairs
(EVARs), four fenestrated EVARs in the context of a clin-
ical trial, eight ruptured EVARs, and 26 PMEGs. Open
procedures comprised seven open infrarenal aneurysm
repairs, one open ruptured aneurysm repair, nine type IV
thoracoabdominal repairs, six pararenal aneurysm repairs,
and three juxtarenal aneurysm repairs.
Fig 3 depicts a summary and ﬂow chart of subject
enrollment to date. During the 16-month study period,
28 patients were consented and 26 underwent the
PMEG procedure (one patient had denial of insurance
OD, Outer diameter.
Fig 1. Arc length example. The length measurement is between the superior mesenteric artery (SMA) and the left renal
artery.
Fig 2. Example of centerline adjustment for enhanced measurement precision in angulated anatomy. A, Automatically
generated centerline showing length measurement from proximal graft and top of left renal to be 34 mm. B, Actual
photograph of physician-modiﬁed endovascular graft (PMEG) device for this subject. C, Angiogram demonstrating
right renal already stented and left renal fenestration positioned too low for proper alignment.D, Centerline adjustment
to mimic path of stiff wire in (C) showing a different length measurement of only 28.3 vs 34 representing
a measurement error of 6 mm. Notice the path of the wire in (C) vs the centerline automatically generated in (A).
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inclusion criteria upon re-review of images). Twenty-ﬁve
patients had 30-day follow-up, 17 patients had 6-month
follow-up, and eight patients had 1-year follow-up. Mean
follow-up for the entire cohort was 11.9 months; 73% of
the subjects were male. Demographics and patient charac-
teristics are listed in Table II, PMEG procedure details are
listed in Table III, and anatomic details of the treatment
group are listed in Table IV.
There were 63 fenestrations created for 48 renal
arteries and 15 superior mesenteric arteries (SMAs). Renal
artery fenestrations were stented whenever possible (96%)
and SMA fenestrations were all left unstented. Two renal
stents were unable to be placed at the initial procedure,
but perfusion to the respective kidneys was maintained.
One patient underwent successful renal stenting the day
following the index procedure and successful aneurysm
exclusion and endograft seal was achieved in each of these
patients.At 30 days, there were no type I or III endoleaks and
only four type II endoleaks (15.4%). Two patients died
during the study period, one at day 23 from respiratory
failure (in-hospital and 30-day mortality ¼ 3.8%)
(Table V) and one at day 210 from urosepsis and conges-
tive heart failure. MAEs occurred in 11.5% of patients at
30 days and included two myocardial infarctions and one
patient experiencing respiratory failure leading to death
(Table VI).
There were no unanticipated adverse device events, no
major adverse device events, and only a single minor
adverse device event at 12 months treated with a successful
reintervention. This subject (003) developed a type III
endoleak because of component separation involving
a left renal stent (Fig 4) and underwent successful reinter-
vention (Fig 5).
The primary efﬁcacy end point was achieved in 87.5%
of patients (technical success 100%, freedoms from migra-
tion, rupture or conversion, type I or III endoleaks, or
Fig 3. Summary and ﬂow chart of subject enrollment to date.
Table II. Demographics and patient characteristics
Demographics No. (%) or mean 6 SD (range)
Age, years 76 6 7.7 (64-90)
Male 19 (73.1)
Coronary artery disease 14 (53.8)
Congestive heart failure 5 (19.2)
Hypertension 25 (96.2)
COPD 10 (38.5)
Diabetes mellitus 8 (30.8)
Hyperlipidemia 21 (80.8)
ASA $ 3 26 (100)
ASA ¼ 4
(including one rupture- 4E)
2 (7.7)
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease; SD, standard deviation.
Table III. PMEG procedure details
Procedural details Mean (range) or %
Graft manufacture time,a minutes 59.7 (31-78)
Operative time, minutes 169 (96-378)
Fluoroscopy time, minutes 42.8 (19.7-164)
Contrast usage, mL 63 (30-120)
Estimated blood loss, mL 221 (20-1000)
General anesthesia, % 96.2
PMEG, Physician-modiﬁed endovascular graft.
aData not available or recorded on four initial patients.
Table IV. Anatomic details of treatment group
Measurement Mean (range)
Maximum aneurysm diameter, mm 62.5 (54-91)
Proximal aortic neck length, mm 4.4 (2-11.7)
Table V. Mortality and lengths of stay
No. (%) or mean 6 SD (range)
30-day mortality 1 (3.8)
ICU length of stay, days 2.8 6 4.4 (0.8-19.7)
Hospital length of stay, days 4.9 6 5.4 (1.3-23.7)
ICU, Intensive care unit.
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tively) (Table VII). Of the eight patients with 1-year
follow-up, seven (87.5%) had evidence of sac shrinkage,
and one patient had sac enlargement.
DISCUSSION
To the layperson, it must seem amazing that even
though fenestrated stent graft technology has existed
worldwide for over a decade, in the United States, we still
do not have an “off-the-shelf” endovascular solution for
patients presenting with juxtarenal aortic aneurysms.
The reasons for this are quite evident, however. Carefully
conducted clinical trials to prove safety and efﬁcacy of
a medical device take time and considerable resources.
Rushing devices to public market before proof of safety
and efﬁcacy is both reckless and hazardous.3 Although
it is exciting that we have a customizable device that is
now FDA approved for commercial use, this is tech-
nology that was innovated 10 years ago and newer
devices and better technologies currently exist in the
“commercial pipeline.”
Faced every day with patients who have limited
options, a few physicians have pushed the limits of currenttechnologies by hearkening back to their surgical roots and
customizing aortic stent grafts using back table modiﬁca-
tions to ﬁt the anatomic needs of the patient.1,4,5 This rai-
ses concerns of quality, product liability, and most of all,
durability. For all of these reasons, we decided to study
this methodology in a carefully controlled prospective clin-
ical trial overseen by the U.S. FDA.
Based on our institutional experience and the results
described in this article, we believe PMEG to be a safe
and durable option for this challenging patient population.
We have learned several valuable lessons along the way.
First, these procedures require advanced imaging,
precise and detailed planning, and technical expertise in
visceral artery intervention. Our procedures typically require
about an hour to manufacture the device, about 2 one-half
hours of operative time with roughly 40 minutes of ﬂuoros-
copy time, and on average only 60 mL of contrast. The
concept of reaching higher in the aorta above the visceral
vessels into a normal and healthy-appearing segment is
counterintuitive at ﬁrst, as it theoretically increases the risk
associated with the procedure. To the contrary, we have
learned that this effort is associated with better ﬁxation
and seal and lessens the risk for graft-related complications
such as migration and/or type I endoleak.
The consistent use of arc length measurements
and centerline adjustments for angulated aortic anatomy
represented signiﬁcant improvements in our operative plan-
ning strategies and subsequent successful conduct of the
procedures. Stent grafts do not always conform to angulated
Table VI. Primary safety end point; MAEs
Procedure,
No. (%)
Postprocedure,
No. (%)
1 month,
No. (%)
6 months,
No. (%)
12 months,
No. (%)
Number of subjects 26 26 25 17 8
Death 0 (0) 0 (0) 1 (4)a 1 (5.9) 0 (0)
Myocardial infarction 0 (0) 2 (11.1) 0 (0) 0 (0) 1 (13)b
Stroke (excludes TIA) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Renal failure (excludes renal insufﬁciency) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Respiratory failure (excludes COPD) 0 (0) 0 (0) 1 (4)a 0 (0) 0 (0)
Paralysis (excludes paraparesis) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Bowel ischemia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Procedural blood loss ($1000 mL) 1 (5.5) 0 (0) 0 (0) 0 (0) 0 (0)
COPD, Chronic obstructive pulmonary disease; MAE, major adverse event; MI, myocardial infarction; TIA, transient ischemic attack.
aThis is the same patient.
bMI 329 days postoperatively.
Fig 4. Subject 003 X-ray at (A) index procedure (July 11, 2011), (B) 1 day postprocedure (July 12, 2011), and (C)
6-month follow-up (December 12, 2011). It is unclear on (C) if there is stent separation. D, Depicts axial computed
tomographic angiogram (CTA) image on August 19, 2011 for 30-day follow-up (no stent separation), and (E) depicts
axial CTA image on December 12, 2011 clearly demonstrating stent separation and type III endoleak (arrow).
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aorta (Fig 2). It may be that this endovascular approach
may not be suitable for patients with severe aortic angulation
and may be associated with less favorable outcomes. We
believe that a thoughtfully and carefully planned PMEG
procedure equates with a technically efﬁcient and well-
executed operative procedure which in turn, translates into
better outcomes for the patient. This can be in the form
of less time under general anesthesia, less contrast usage,
and less ischemic time to the lower extremities.
As reported previously, our results compare favorably
with contemporary results of fenestrated endografting in
the current medical literature.6-10 In this early series,
PMEG was associated with a 3.8% 30-day mortality rate ina single patient who died of respiratory failure on post-
operative day 23. In our initial report on PMEG, our average
number of fenestrations per patient was 1.75 compared
with two to three in other studies.6,9,11 In the current
series, the average number of fenestrations per case was
2.5. This is probably reﬂective of our learning curve over a
5-year period and the realization that “higher was better.”
Others have criticized our strategy of routinely leaving
the SMA unstented. This is a valid criticism but must be
explained. The reason for this strategy is related to current
device constraints and nothing else. Our goal is to leave the
renal fenestrations completely strut free and to use a large
(w12 mm) fenestration for the SMA. This typically
involves struts spanning the SMA fenestration because of
Fig 5. Subject 003 underwent secondary intervention on
February 21, 2012. A, Depicts component separation and type III
endoleak (arrow). This subject underwent successful placement of
a second covered stent (B) and had resolution of endoleak (C).
Table VII. Primary effectiveness end point; treatment
success
Criteria No. (%)
Technical success 26/26 (100)
Freedom from migration at 12 months 8/8 (100)
Freedom from rupture or conversion at 12 months 8/8 (100)
Freedom from type I or III endoleak at 12 months 7/8 (87.5)a
Freedom from sac enlargement at 12 months 7/8 (87.5)a
aThe same patient (subject 003) had sac enlargement from a type III
endoleak successfully treated with secondary intervention.
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of a stent into this fenestration would potentially lead to
stent failure because of the interaction between the stent
and struts.
There was a single minor adverse device event in this
series. Interestingly, it involved stent separation of a left-
sided renal artery stent. Renal artery deformation with
respiration has been previously reported, but the impact
of this phenomenon on renal artery stent durability is ill
deﬁned.12,13 Left renal artery stent fractures are thought
to be more common that right-sided fractures.12 Future
stent designs may demand speciﬁc characteristics to over-
come these challenges, as it seems that in this region of
the aorta, the Achilles’ heel of any branched or fenestrated
stent graft technology is the renal artery.
With recent FDA approval of the Z-Fen device (Cook,
Incorporated), we have observed that many patientscurrently managed with PMEG can undergo treatment
with this commercially available system. There will,
however, continue to be a need for a truly off-the-shelf
device applicable to most patients or a customizable device,
like PMEG, for those patients requiring urgent or semi-
urgent repair. It should be clearly emphasized that the
PMEG fenestrated procedure as described in this article
should only be used for juxtarenal and not pararenal aneu-
rysms. Physician-modiﬁed endografts can be used to treat
suprarenal aneurysms as well, but this is not within the
scope of this report.
CONCLUSIONS
This early report on PMEGs is encouraging and
suggests that the technique is valid, safe, and effective, at
least in the short term. This endovascular aortic strategy
is particularly appealing for those patients presenting with
symptomatic or ruptured aortic aneurysms until reliable
off-the-shelf solutions become widely available. Durability
issues have not been proven and will be determined by
mid- and long-term results.
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sented his early results from the IDE clinical trial on PMEGs in
a series of 26 patients with juxtarenal aortic aneurysms. He is to
be congratulated in achieving excellent early outcomes with
limited tools on the back table.
In a custom-made device, it is possible to place the fenestra-
tions in the optimum position to match the patient’s anatomy
and adjust the stents to ﬁt around them, but when fenestrations
are made on an already-sterile graft, it may be necessary to place
the fenestrations in a perhaps less-than-optimum position to ﬁt
in between the stent struts. The fact that Dr Starnes can achieve
a 100% technical success rate is testimony to his planning skills
and technical expertise.
Devices modiﬁed in this manner were by all accounts similar
to the early fenestrated grafts that were made and implanted in
other patients outside the United States. Although the follow-up
period of this present series is a mere 11 months, there is no
reason to suspect that longer-term outcomes would not be as
good, if not better, than those published by the same group in
this month’s Journal of Vascular Surgery. In the inevitable
comparison between the two series, it is evident that a larger
number of fenestrations were used in the later IDE trial, in partic-
ular for the SMA. The authors attributed this to a need to
maximize proximal seal.
I have the following questions for Ben:
You addressed the issue of not stenting the SMA due to limi-
tations of the stent struts crossing the large fenestration. In this
manner, the SMA fenestration essentially functions as a large
scallop and cannot add much to extending the proximal seal.
In your opinion, would that limit the PMEGs to treating juxtare-
nal aneurysms, but not true suprarenal aneurysms? Have you
used this graft to treat aneurysms with less than the 2-mm
neck length?
On a technical note, when you used nitinol snares around the
fenestrations, do these function only as a radiopaque marker? In
standard fenestrated grafts, the nitinol reinforcing rings help to
lock the stents onto the fenestration and allow for better ﬂaring.
Unreinforced fenestrations may stretch and expand in size to the
diameter of virtually any balloon that was used, and the origin ofthe target vessel could be expanded to more than would be consid-
ered safe. Do you see these as concerns for long-term failure?
Finally, in light of the competing fenestrated systems such as
the Ventana and the Anaconda, or the newer-generation Zenith
p-branch off-the-shelf devices, how do you see the role of physi-
cian-modiﬁed grafts in the future?
I thank the society for the opportunity to discuss this paper.
Dr Benjamin Ware Starnes. Thank you, Stephen, for those
insightful comments. Regarding the SMA fenestration remaining
unstented, I do not believe that this fenestration serves merely as
a scallop. In fact, with PMEG, I have found that the creation of
a scallop using these techniques actually disrupts the integrity of
the proximal graft fabric and makes the device more difﬁcult to
reload into the sheath. Also, there is actually quite good seal in
and around the unstented SMA fenestration in these cases.
Remember that we are conﬁned by the standard Cook device
design and try at all costs to leave the renal fenestrations strut-
free. This then, in the majority of situations, leaves struts spanning
the SMA fenestration. Stenting the SMA in this situation, I believe
is fraught with hazard to include stent kinking and crushing with
greater radial strength of the existing struts over the renal stents.
This leads to the second part of your ﬁrst question which isd
PMEG is really only for true juxtarenal aneurysms with at least 2
mm of neck below the renal arteries, not for para- or suprarenal
aneurysms. All of these patients had at least 2 mm of neck with
a range of between 2 and 11 mm.
The gold markers are hand sewn into place using 4-0 prolene
in a 720 circumferential fashion, so while not being a true rein-
forced fenestration, with good aortic wall apposition and parallel
walls, I believe this is a durable alternative. One of the beneﬁts
of this IDE is going to be the ability to assess the durability of
this approach over the long term.
Finally, even with off-the-shelf solutions in the industrial pipe-
line, I still believe that there will be a role for PMEG in speciﬁc
anatomic situations. These grafts are truly customized to each
and every patient, and time will tell if they are even more durable
than an off-the-shelf solution to manage more than just 70% of
patients with juxtarenal aortic aneurysms, which is what these
new grafts tout.
